7.06
price up icon3.22%   0.22
after-market Handel nachbörslich: 7.06
loading
Schlusskurs vom Vortag:
$6.84
Offen:
$6.72
24-Stunden-Volumen:
944.80K
Relative Volume:
0.27
Marktkapitalisierung:
$314.00M
Einnahmen:
$124.00K
Nettoeinkommen (Verlust:
$-49.99M
KGV:
-4.1775
EPS:
-1.69
Netto-Cashflow:
$-31.03M
1W Leistung:
-8.19%
1M Leistung:
-18.19%
6M Leistung:
+7.79%
1J Leistung:
+434.85%
1-Tages-Spanne:
Value
$6.63
$7.2692
1-Wochen-Bereich:
Value
$6.45
$7.61
52-Wochen-Spanne:
Value
$1.16
$14.60

Candel Therapeutics Inc Stock (CADL) Company Profile

Name
Firmenname
Candel Therapeutics Inc
Name
Telefon
617-916-5445
Name
Adresse
117 KENDRICK STREET, NEEDHAM
Name
Mitarbeiter
42
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
CADL's Discussions on Twitter

Vergleichen Sie CADL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CADL
Candel Therapeutics Inc
7.06 314.00M 124.00K -49.99M -31.03M -1.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
439.73 113.24B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
694.64 76.33B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
652.19 39.00B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
275.54 35.54B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
122.12 29.28B 3.30B -501.07M 1.03B -2.1146

Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-12-02 Eingeleitet H.C. Wainwright Buy
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-08-23 Eingeleitet Credit Suisse Outperform
2021-08-23 Eingeleitet Jefferies Buy
2021-08-23 Eingeleitet UBS Buy

Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten

pulisher
Jan 22, 2025

How to Take Advantage of moves in (CADL) - Stock Traders Daily

Jan 22, 2025
pulisher
Jan 18, 2025

Seshu Tyagarajan Sells 14,322 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock - MarketBeat

Jan 18, 2025
pulisher
Jan 18, 2025

Insider Stock Buying Of Candel Therapeutics Delivers Return On US$3.00m Investment - Yahoo Finance

Jan 18, 2025
pulisher
Jan 16, 2025

Candel Therapeutics (NASDAQ:CADL) versus INmune Bio (NASDAQ:INMB) Head-To-Head Review - Defense World

Jan 16, 2025
pulisher
Jan 15, 2025

Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Drops By 33.0% - MarketBeat

Jan 15, 2025
pulisher
Jan 14, 2025

Candel Therapeutics provides corporate update, highlights momentum - TipRanks

Jan 14, 2025
pulisher
Jan 13, 2025

Candel Therapeutics advancing lead candidate targeting prostate cancer towards FDA submission - Proactive Investors USA

Jan 13, 2025
pulisher
Jan 13, 2025

Candel Therapeutics Highlights Pipeline Progress and Stability - TipRanks

Jan 13, 2025
pulisher
Jan 13, 2025

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025 - The Manila Times

Jan 13, 2025
pulisher
Jan 11, 2025

Candel therapeutics CMO sells $88,749 in stock By Investing.com - Investing.com Australia

Jan 11, 2025
pulisher
Jan 11, 2025

Where are the Opportunities in (CADL) - Stock Traders Daily

Jan 11, 2025
pulisher
Jan 11, 2025

Candel therapeutics CMO sells $88,749 in stock - Investing.com India

Jan 11, 2025
pulisher
Jan 10, 2025

Candel Therapeutics CTO sells shares worth $119,533 By Investing.com - Investing.com Australia

Jan 10, 2025
pulisher
Jan 10, 2025

Candel therapeutics chief scientific officer sells $112,367 in stock By Investing.com - Investing.com Canada

Jan 10, 2025
pulisher
Jan 10, 2025

Candel therapeutics chief scientific officer sells $112,367 in stock - Investing.com India

Jan 10, 2025
pulisher
Jan 10, 2025

Insider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells 13,673 Shares of Stock - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

Candel Therapeutics CEO sells shares worth $173,995 By Investing.com - Investing.com Canada

Jan 10, 2025
pulisher
Jan 10, 2025

Candel Therapeutics CTO sells shares worth $119,533 - Investing.com India

Jan 10, 2025
pulisher
Jan 10, 2025

Candel Therapeutics interim CFO Charles Schoch sells $81,943 in stock By Investing.com - Investing.com Canada

Jan 10, 2025
pulisher
Jan 09, 2025

After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win - PharmaVoice

Jan 09, 2025
pulisher
Jan 08, 2025

Candel Therapeutics’ $92 Million Common Stock Offering - Global Legal Chronicle

Jan 08, 2025
pulisher
Jan 08, 2025

Top 5 Small-cap Biotech Stocks (Updated January 2025) - Nasdaq

Jan 08, 2025
pulisher
Jan 08, 2025

How Is The Market Feeling About Candel Therapeutics? - Benzinga

Jan 08, 2025
pulisher
Jan 07, 2025

Barclays PLC Boosts Stock Holdings in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World

Jan 07, 2025
pulisher
Jan 07, 2025

Geode Capital Management LLC Buys 51,111 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World

Jan 07, 2025
pulisher
Jan 06, 2025

Institutions profited after Candel Therapeutics, Inc.'s (NASDAQ:CADL) market cap rose US$41m last week but retail investors profited the most - Simply Wall St

Jan 06, 2025
pulisher
Jan 06, 2025

Outlook Therapeutics (NASDAQ:OTLK) versus Candel Therapeutics (NASDAQ:CADL) Financial Survey - Defense World

Jan 06, 2025
pulisher
Jan 01, 2025

Top 5 Biotech Stocks Dominating Retail Investor Conversations In 2024 - MSN

Jan 01, 2025
pulisher
Jan 01, 2025

When the Price of (CADL) Talks, People Listen - Stock Traders Daily

Jan 01, 2025
pulisher
Dec 31, 2024

State Street Corp Boosts Stake in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World

Dec 31, 2024
pulisher
Dec 28, 2024

MML Investors Services LLC Sells 51,063 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World

Dec 28, 2024
pulisher
Dec 27, 2024

Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Up 109.6% in December - MarketBeat

Dec 27, 2024
pulisher
Dec 26, 2024

Largest borrow rate increases among liquid names - TipRanks

Dec 26, 2024
pulisher
Dec 26, 2024

6,573 Shares in Candel Therapeutics, Inc. (NASDAQ:CADL) Acquired by Fmr LLC - Defense World

Dec 26, 2024
pulisher
Dec 25, 2024

Critical Review: 4D Molecular Therapeutics (NASDAQ:FDMT) & Candel Therapeutics (NASDAQ:CADL) - Defense World

Dec 25, 2024
pulisher
Dec 23, 2024

2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive financial news

Dec 23, 2024
pulisher
Dec 21, 2024

Research Analysts Set Expectations for CADL FY2024 Earnings - Defense World

Dec 21, 2024
pulisher
Dec 19, 2024

Candel Therapeutics Shares Leap on Chairman Purchase - MarketWatch

Dec 19, 2024
pulisher
Dec 19, 2024

Candel Therapeutics rides high on promising Phase 3 data, funding boost - Proactive Investors UK

Dec 19, 2024
pulisher
Dec 19, 2024

Candel Therapeutics Inc call volume above normal and directionally bullish - TipRanks

Dec 19, 2024
pulisher
Dec 18, 2024

Insider Buying: Candel Therapeutics, Inc. (NASDAQ:CADL) Director Purchases 1,250,000 Shares of Stock - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

Candel Therapeutics stock upgraded as CAN-2409 delivers in prostate cancer trial - Investing.com Australia

Dec 18, 2024
pulisher
Dec 18, 2024

Candel Therapeutics stock upgraded as CAN-2409 delivers in prostate cancer trial By Investing.com - Investing.com South Africa

Dec 18, 2024
pulisher
Dec 18, 2024

Candel Therapeutics aims to transform cancer outcomes - Proactive financial news

Dec 18, 2024
pulisher
Dec 18, 2024

HC Wainwright Reiterates Buy Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat

Dec 18, 2024
pulisher
Dec 17, 2024

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - The Manila Times

Dec 17, 2024
pulisher
Dec 16, 2024

Candel Therapeutics Raises $92M in Oversubscribed Public Offering to Advance Cancer Drug Development - StockTitan

Dec 16, 2024
pulisher
Dec 16, 2024

Candel Therapeutics raises $92M in public offering following prostate cancer trial success - Proactive Investors USA

Dec 16, 2024

Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$72.53
price up icon 0.17%
$42.39
price up icon 10.10%
$371.89
price up icon 0.16%
$24.65
price up icon 4.80%
biotechnology ONC
$222.24
price up icon 0.01%
$122.12
price up icon 6.03%
Kapitalisierung:     |  Volumen (24h):